☆ 4.7 Article

Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan

HYPERTENSION (2008)

Journal

HYPERTENSION

Volume 51, Issue 2, Pages 296-301

Publisher

LIPPINCOTT WILLIAMS & WILKINS

DOI: 10.1161/HYPERTENSIONAHA.107.099044

Keywords

cardiac remodeling; endothelium; hypertension; reactive oxygen species; inflammation; peroxisome proliferator-activated receptor gamma; AT1 receptor

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

The effect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on hypertensive cardiovascular injury is unknown. We examined the effect of pioglitazone on hypertensive cardiovascular injury and the significance of combination of pioglitazone with angiotensin type 1 receptor blocker. Stroke-prone spontaneously hypertensive rats ( SHRSP) were orally given pioglitazone, candesartan, or combined pioglitazone and candesartan for 4 weeks to compare their effects on cardiovasucular injury. Pioglitazone, without lowering blood pressure, significantly suppressed cardiac inflammation and fibrosis and reduced vascular endothelial dysfunction, and these beneficial effects were associated with the reduction of superoxide by inhibition of cardiovascular NADPH oxidase. Thus, pioglitazone protects against hypertensive cardiovascular injury, by inhibiting reactive oxygen species ( ROS). Combination of pioglitazone and candesartan suppressed cardiac hypertrophy, inflammation, and interstitial fibrosis of SHRSP to a greater extent than either monotherapy, and reduced vascular endothelial dysfunction of SHRSP more than either monotherapy. Furthermore, more beneficial effects of their combination on cardiovascular injury were associated with more reduction of NADPH oxidase - mediated cardiovascular ROS. To elucidate the underlying molecular mechanism, we examined cardiovascular NADPH oxidase subunits. Pioglitazone monotherapy significantly attenuated cardiovascular p22(phox) and Rac1 in SHRSP, whereas pioglitazone combined with candesartan more attenuated p22(phox) and significantly reduced Nox1. Thus, additive suppression of cardiovascular NADPH oxidase by the combination was attributed to its additive attenuation of p22phox and Nox1 protein levels. In conclusion, we showed that pioglitazone protected against hypertensive cardiovascular damage, and the combination of pioglitazone and candesartan exerted more beneficial effects on hypertensive cardiovascular injury by more suppressing ROS.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Role of the Peroxisome Proliferator Activated Receptors in Hypertension

Shi Fang, M. Christine Livergood, Pablo Nakagawa, Jing Wu, Curt D. Sigmund

Summary: This review focuses on the mechanisms by which nuclear receptors mediate transcriptional responses, with a specific emphasis on the role of PPARγ in regulating blood pressure. Genetic and clinical trial data demonstrate the importance of PPARγ in hypertension, and the tissue- and cell-specific molecular mechanisms by which PPARs modulate blood pressure and related phenotypes are detailed. The role of placental PPARs in preeclampsia is also discussed, along with future research directions and implications for novel therapies.

CIRCULATION RESEARCH (2021)